Skip to content
Open access

Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer

Aug 2026 · Frontiers in Artificial Intelligence · Vol 9 · 0 citations · 17 references
Medicine

Abstract

Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecular digital twins of individual participants using a Bayesian foundation model of cancer (FarrSight®) in the COMPASS clinical trial (a non-randomized study of mFOLFIRINOX and gemcitabine + nab-paclitaxel in first-line advanced pancreatic cancer). We compared these individual digital twin predictions to the existing Moffitt classification of pancreatic ductal adenocarcinoma. Individual digital twin predictions of response to mFOLFIRINOX outperformed the Moffitt classification in the basal-like subtype with an AUC of 72.3% compared to the conventional biomarker AUC of 44.8%; overall accuracy of 65.8% vs. 47.4%; PPV of 60% vs. 40%; and NPV of 72.2% vs. 52.2%. Individual patient response predictions using models such as FarrSight® have the potential to better select patients for treatment with established therapeutics and in therapeutic development compared to biomarkers based on population averages.

Read PDF

Similar papers

#artificial intelligence Preprint Sep 2026

Causal multi-modal AI for personalized chemosensitivity prediction

The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.

D. Biswas, Jeroen Berrevoets, A. McClean et al. · 3 citations
Review Open access Sep 2026

Molecular therapy matching score correlates with clinical outcomes: a system for navigating cancer complexity

An algorithmic Matching Score is described that evaluates cancer drugs’/drug combinations’ ability to address a patients’ entire next-generation sequencing/multi-omic-derived molecular profile and underscores the clinical importance of the precision medicine approach that maximizes matching of multiple molecular altera...

Ally Perlina, Subha Krishnan, K. Bush et al. · 0 citations
Open access Sep 2026

Deep Learning-Based Multi-Cancer Analysis for Predicting Disease-Free Survival Across Multiple Cancer Types

The deep learning-based multi-cancer disease-free survival model performed robustly across cancer subtypes, with the nomogram improving risk stratification, particularly for stage I malignancies, complementing existing staging.

Si-Teng Chen, En-Cheng Zhang, Fu-Kang Sun et al. · 0 citations
#federated learning Review Open access Sep 2026

Digital Twins in Oncology: From Multimodal Data Integration to Precision Clinical Practice

This narrative review provides radiologists with a balanced, comprehensive overview of digital twin architecture, advanced enabling technologies, current clinical evidence, a practical roadmap for implementation, and a candid appraisal of barriers to adoption.

Annamalai Vairavan, Rupsa Bhattacharjee, B. Raghavan · 0 citations
Open access Aug 2026

Identifying multi-omics biomarkers for ovarian cancer survival estimation

An interpretable three-stage machine learning framework integrating mRNA, microRNA, DNA methylation, copy number variation, and protein expression data from The Cancer Genome Atlas that couples improved prognostic estimation with biological interpretability supporting multi-omics biomarker discovery in ovarian cancer.

Kosar Fateh, S. Sathipati · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.